Takeda Terminates Global Sales And Development Agreement With Amylin
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and American Amylin Pharmaceuticals have agreed to terminate the contract the companies signed in October 2009 regarding joint sales and development of anti-obesity drugs.